Cantargia AB (publ) (CANTA.ST)
SEK 1.21
(-6.56%)
SEK 1.21
(-6.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -284.31 Million SEK | 22.77% |
| 2022 | -375.95 Million SEK | -1.39% |
| 2021 | -363.05 Million SEK | -113.77% |
| 2020 | -169.83 Million SEK | -53.12% |
| 2019 | -110.79 Million SEK | -21.65% |
| 2018 | 1.61 Million SEK | -51.3% |
| 2017 | -453 Thousand SEK | -35.08% |
| 2016 | -91 Thousand SEK | -162.52% |
| 2015 | -16.99 Million SEK | -109.36% |
| 2014 | -8.37 Million SEK | -2.16% |
| 2013 | -7.94 Million SEK | -129.31% |
| 2012 | -3.46 Million SEK | -2.34% |
| 2011 | -3.38 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -42.42 Million SEK | -17.54% |
| 2024 Q1 | -40.35 Million SEK | 48.93% |
| 2023 Q3 | -74.16 Million SEK | -33.54% |
| 2023 Q1 | -75.05 Million SEK | 16.47% |
| 2023 Q4 | -70.68 Million SEK | 4.69% |
| 2023 Q2 | -55.53 Million SEK | 26.0% |
| 2023 FY | - SEK | 22.77% |
| 2022 Q3 | -73.35 Million SEK | 19.77% |
| 2022 FY | - SEK | -1.39% |
| 2022 Q1 | -116.59 Million SEK | -12.86% |
| 2022 Q4 | -89.84 Million SEK | -22.48% |
| 2022 Q2 | -91.42 Million SEK | 21.59% |
| 2021 Q2 | -85.73 Million SEK | -19.51% |
| 2021 Q1 | -71.74 Million SEK | -28.96% |
| 2021 Q3 | -102.96 Million SEK | -20.1% |
| 2021 Q4 | -103.3 Million SEK | -0.33% |
| 2021 FY | - SEK | -113.77% |
| 2020 FY | - SEK | -53.12% |
| 2020 Q1 | -38.89 Million SEK | -7.21% |
| 2020 Q2 | -36.86 Million SEK | 5.2% |
| 2020 Q3 | -38.58 Million SEK | -4.66% |
| 2020 Q4 | -55.63 Million SEK | -44.18% |
| 2019 Q1 | -23.52 Million SEK | 15.56% |
| 2019 FY | - SEK | -21.65% |
| 2019 Q4 | -36.27 Million SEK | -39.52% |
| 2019 Q3 | -26 Million SEK | -3.95% |
| 2019 Q2 | -25.01 Million SEK | -6.33% |
| 2018 Q3 | -21.41 Million SEK | 23.93% |
| 2018 Q1 | -13.69 Million SEK | 18.1% |
| 2018 Q4 | -27.85 Million SEK | -30.1% |
| 2018 Q2 | -28.14 Million SEK | -105.46% |
| 2018 FY | - SEK | -51.3% |
| 2017 FY | - SEK | -35.08% |
| 2017 Q3 | -11.05 Million SEK | 27.7% |
| 2017 Q2 | -15.29 Million SEK | 10.93% |
| 2017 Q1 | -17.17 Million SEK | -6.2% |
| 2017 Q4 | -16.72 Million SEK | -51.26% |
| 2016 Q2 | -7.92 Million SEK | 2.12% |
| 2016 Q3 | -12.48 Million SEK | -57.55% |
| 2016 Q4 | -16.17 Million SEK | -29.51% |
| 2016 FY | - SEK | -162.52% |
| 2016 Q1 | -8.09 Million SEK | -61.92% |
| 2015 Q4 | -5 Million SEK | -59.91% |
| 2015 FY | - SEK | -109.36% |
| 2015 Q3 | -3.12 Million SEK | 42.43% |
| 2015 Q2 | -5.43 Million SEK | -54.69% |
| 2015 Q1 | -3.51 Million SEK | -44.15% |
| 2014 FY | - SEK | -2.16% |
| 2014 Q1 | -1.86 Million SEK | -10492.2% |
| 2014 Q3 | -1.97 Million SEK | -8.0% |
| 2014 Q4 | -2.43 Million SEK | -23.05% |
| 2014 Q2 | -1.83 Million SEK | 1.79% |
| 2013 FY | - SEK | -129.31% |
| 2013 Q4 | 17.96 Thousand SEK | 0.0% |
| 2012 FY | - SEK | -2.34% |
| 2011 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | -1171.363% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 10.442% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | -0.809% |
| Xintela AB (publ) | -53.47 Million SEK | -431.718% |
| Active Biotech AB (publ) | -43.88 Million SEK | -547.834% |
| Amniotics AB (publ) | -27.14 Million SEK | -947.471% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -1899.824% |
| BioArctic AB (publ) | 275.38 Million SEK | 203.242% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 22.699% |
| Camurus AB (publ) | 562.54 Million SEK | 150.541% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -1352.143% |
| CombiGene AB (publ) | -35.33 Million SEK | -704.603% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -101.855% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -1564.168% |
| Genovis AB (publ.) | 64.57 Million SEK | 540.307% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -147.431% |
| Mendus AB (publ) | -97.84 Million SEK | -190.574% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -667.921% |
| Intervacc AB (publ) | -68.98 Million SEK | -312.17% |
| Kancera AB (publ) | -61.88 Million SEK | -359.395% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -961.55% |
| LIDDS AB (publ) | -39.67 Million SEK | -616.7% |
| Lipum AB (publ) | -37.11 Million SEK | -665.955% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -2248.934% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 1005.346% |
| NextCell Pharma AB | -40.98 Million SEK | -593.702% |
| OncoZenge AB (publ) | 7.26 Million SEK | 4012.951% |
| Saniona AB (publ) | -69.69 Million SEK | -307.942% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -67.426% |
| Ziccum AB (publ) | -20.34 Million SEK | -1297.675% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 14215850.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | -19.654% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -13568.99% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -2016.857% |
| Corline Biomedical AB | -1.69 Million SEK | -16713.424% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | -64.037% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -418.766% |
| Aptahem AB (publ) | -10 Million SEK | -2740.529% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 2561.815% |
| Fluicell AB (publ) | -25.91 Million SEK | -997.148% |
| Biovica International AB (publ) | -119.5 Million SEK | -137.909% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -573.349% |
| AcouSort AB (publ) | -16.7 Million SEK | -1602.179% |
| Abliva AB (publ) | -93.6 Million SEK | -203.729% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 10.901% |
| 2cureX AB (publ) | -35.13 Million SEK | -709.184% |
| I-Tech AB | 30.34 Million SEK | 1036.942% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 60.211% |
| Cyxone AB (publ) | -20.41 Million SEK | -1292.745% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -177.508% |
| Biosergen AB | 228 Thousand SEK | 124799.561% |
| Nanologica AB (publ) | -62.11 Million SEK | -357.694% |
| SynAct Pharma AB | -222.7 Million SEK | -27.667% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -548.218% |
| BioInvent International AB (publ) | -312.7 Million SEK | 9.079% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 91988.511% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 677056.594% |
| Oncopeptides AB (publ) | -231.62 Million SEK | -22.75% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -3126.278% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -161.901% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -2378.987% |